Ophthalmic surgery, lasers & imaging retina · 2015
Predictability of Recurrent Exudation and Subretinal Hemorrhaging in Neovascular Age-Related Macular Degeneration With Indocyanine Green Angiography.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Rush Ryan B, Rush Sloan W, Aragon Antonio V, Ysasaga J Edward
Аннотация
BACKGROUND AND OBJECTIVE: To report the predictability of recurrent exudation and subretinal hemorrhaging after treatment extension in neovascular age-related macular degeneration (AMD) through assessment of interval changes in choroidal neovascularization (CNV) size on indocyanine green (ICG) angiography.
PATIENTS AND METHODS: The charts of patients with neovascular AMD who underwent bevacizumab therapy using a treat-and-extend protocol were retrospectively reviewed over a 12-month period.
RESULTS: An increase of 33% or more in CNV surface area on ICG angiography from 4 to 6 weeks, 6 to 8 weeks, and 8 to 10 weeks was observed in patients whose treatment interval could not be extended from 6 to 8 weeks, 8 to 10 weeks, and 10 to 12 weeks, respectively, and this was significant compared to patients whose treatment interval was successfully extended during those respective intervals (P < .0001, P = .0002, P = .0004, respectively).
CONCLUSION: CNV size change on ICG angiography can predict which patients are likely to experience recurrent exudation and/or subretinal hemorrhaging after treatment extension using treat-and-extend bevacizumab.
PATIENTS AND METHODS: The charts of patients with neovascular AMD who underwent bevacizumab therapy using a treat-and-extend protocol were retrospectively reviewed over a 12-month period.
RESULTS: An increase of 33% or more in CNV surface area on ICG angiography from 4 to 6 weeks, 6 to 8 weeks, and 8 to 10 weeks was observed in patients whose treatment interval could not be extended from 6 to 8 weeks, 8 to 10 weeks, and 10 to 12 weeks, respectively, and this was significant compared to patients whose treatment interval was successfully extended during those respective intervals (P < .0001, P = .0002, P = .0004, respectively).
CONCLUSION: CNV size change on ICG angiography can predict which patients are likely to experience recurrent exudation and/or subretinal hemorrhaging after treatment extension using treat-and-extend bevacizumab.
Предметные рубрики MeSH
AgedAged, 80 and overAngiogenesis InhibitorsBevacizumabColoring AgentsExudates and TransudatesFemaleFluorescein AngiographyHumansIndocyanine GreenIntravitreal InjectionsMaleRecurrenceRetinal HemorrhageRetrospective StudiesSubretinal FluidTomography, Optical CoherenceVascular Endothelial Growth Factor AVisual AcuityWet Macular Degeneration